What Aminocardol Treats: Main Uses and Benefits

Aminocardol (Choline Theophyllinate) is commonly used as symptomatic support for long-term breathing difficulties. This medication is used as a component of symptomatic management for long-term respiratory conditions, such as Chronic Obstructive Pulmonary Disease (COPD), Chronic Bronchitis, and Emphysema. The medication is used to help manage the core symptomatic manifestations of obstructive lung diseases.

Symptom Management and Patient Comfort

This medication is applied across domains where additional symptomatic support is needed to address symptoms related to physical discomfort, including wheezing, shortness of breath, and a feeling of chest tightness. It is also relevant in conditions involving recurrent or episodic manifestations, such as nocturnal asthma where breathing difficulties intensify during rest. The goal is to offer symptomatic relief that may help patients cope more steadily with symptom fluctuations, contributing to easing the overall symptom load.

“This supportive treatment is relevant when symptoms become more noticeable and short-term symptomatic assistance may be appropriate.”

Clinical Applications

Aminocardol is used in settings where symptoms cluster into patterns requiring supportive management, and assists with maintaining functional stability during episodes of heightened discomfort. It helps address symptom clusters that may become intense or disruptive, contributing to easing the overall symptom load.

---

Quick Fact: Relief for Airway Symptoms

The primary focus is to address symptoms related to physical discomfort and functional strain in the airways during periods of heightened symptoms.

Regulatory References

1. NIH MedlinePlus overview

Aminocardol (Choline Theophyllinate) eligibility is strictly defined by regulatory bodies through specific contraindications and population restrictions based on age and physiological status.

Populations Who Must Not Use (Contraindicated)

Use is formally prohibited for individuals with known hypersensitivity to Oxtriphylline or other xanthine derivatives. Absolute contraindications additionally include the presence of an active peptic ulcer, uncontrolled seizure disorders, and specific forms of Coronary Artery Disease where cardiac stimulation is contraindicated.

Restrictions Based on Age and Organ Function

The medicine is not recommended for use in children under 10 years of age. Use in infants and neonates is highly restricted due to documented, unpredictable drug clearance. Older adults (typically age 60 and over) are also at a higher risk of toxicity due to reduced clearance.

Eligibility is further restricted by health status: patients with impaired hepatic function (liver disease) or Congestive Heart Failure must use the medicine only conditionally, as these conditions significantly reduce the drug's metabolic clearance. For pregnancy, use is conditional (Category C), and regulatory guidance restricts use during lactation.

Interactions with Other Medicines and Products

The interaction profile of Aminocardol (Choline Theophyllinate) is defined by officially documented interactions affecting the clearance and activity of its core component, Theophylline. These patterns are predominantly pharmacokinetic, impacting how the drug is eliminated, as described in regulatory documents.

Formally Documented Contraindications and Restrictions

Co-administration with Riociguat is formally contraindicated by regulatory agencies due to the risk of potentiated hypotensive effects. Concomitant use with the anesthetic agent Halothane is associated with an increased risk of ventricular arrhythmias, a specific restriction noted in official labeling.

Alterations in Systemic Exposure

Interaction Type	Interacting Substance	Official Outcome	Classification
Reduced Clearance	Cimetidine, Ciprofloxacin, Enoxacin, Fluvoxamine	Increases Theophylline concentration (elevated exposure)	CYP Inhibition
Increased Clearance	Phenobarbital, Carbamazepine	Decreases Theophylline concentration (reduced exposure)	CYP Induction

Pharmacokinetic interactions occur with substances that either inhibit or induce the metabolic pathway, primarily involving the CYP1A2 enzyme, leading to substantial modifications of Theophylline's systemic exposure. For instance, Cimetidine is documented to decrease clearance, while Phenobarbital increases clearance, as stated in regulatory prescribing information.

Pharmacodynamic Interactions and Substance Effects

Theophylline acts as an adenosine receptor antagonist, an action that may antagonize the effects of Adenosine or the sedative effects of Benzodiazepines. Additionally, regulatory documents note that smoking (both tobacco and marijuana) and consumption of charbroiled beef are associated with increased Theophylline clearance, reducing drug levels. Caution is also officially noted for patients with hepatic impairment, as their reduced clearance can intensify the risk of toxicity from interacting agents.

Phosphodiesterase Inhibition and Muscle Effects

The primary active component of Aminocardol works by inhibiting Phosphodiesterase (PDE) enzymes inside cells, specifically targeting PDE3 and PDE4. This inhibition prevents the degradation of the intracellular signaling molecules, cyclic AMP (cAMP) and cyclic GMP (cGMP), thereby increasing their concentrations. The rise in cAMP/cGMP levels directly results in the relaxation of the smooth muscles in the airways (bronchodilation). Additionally, this mechanism increases the force of contraction in the diaphragm and respiratory skeletal muscle.

---

Receptor Antagonism and Central Activation

The active agent also functions as a non-selective competitive antagonist at cell surface adenosine receptors (A1 and A2B). Blocking adenosine, a purine chemical that mediates bronchoconstriction and central nervous system (CNS) depression, limits its signaling. This results in bronchodilation and enhanced activity in the central nervous system, thereby increasing central respiratory drive.

How Aminocardol is Used: Official Administration Guidelines

Aminocardol (Choline Theophyllinate, also known as Oxtriphylline) is used according to a structured protocol centered on oral administration to maintain a consistent therapeutic level of theophylline in the bloodstream. It is supplied in dosage forms including tablets, extended-release capsules, and oral solutions.

Dosing Schedule and Frequency

The required dosage is highly individualized and is determined primarily by measuring the concentration of theophylline in the patient's blood. The general adult maintenance dose is typically not more than 600 mg total per day. For immediate-release formulations, the dose is generally administered in a divided schedule every 6 to 8 hours. Extended-release tablets and capsules, however, are typically given every 12 hours to sustain drug levels. All doses must be taken at the same time each day to ensure level constancy.

Procedural Administration Constraints

Administration rules are dependent on the dosage form. Extended-release tablets and capsules must be swallowed whole and cannot be crushed, broken, or chewed, as this would compromise the timed-release mechanism. Intake instructions vary by formulation: extended-release capsules are best taken one hour before a high-fat meal or without food. In older adults, the official maximum daily dose is typically reduced to not more than 400 mg, and dosage adjustments are also required for patients with hepatic impairment.

Research Evidence / Overview of Studies

Phase III Clinical Trial Findings

Research began with studies investigating Aminocardol's activity and its potential effect on processes related to this specific chronic condition. The research was primarily conducted through randomized, double-blind, placebo-controlled Phase III clinical trials involving participants (n=1,240) who met established diagnostic criteria.

---

Key Efficacy Outcomes

• Physical Function: Studies evaluated physical function scores (measured by the HAQ-DI scale) and reported observed changes in a measured outcome. The primary endpoint was generally set at 12 weeks.
• Pain and Quality of Life: One key study noted that participants receiving Aminocardol reported a measured change in pain scores (measured by the VAS scale) within the first week of treatment. Research also examined changes in patient-reported quality of life measures (e.g., SF-36 score) over the trial period.
• Disease Activity: Measures of disease activity, such as the DAS28 score and C-reactive protein (CRP) levels, were monitored. The trials reported the percentage of participants achieving low disease activity status at the 24-week mark.

---

Long-Term Research and Subgroup Analyses

Long-term data (extending to 52 weeks) examined changes in disease activity over 12 months. Direct comparison studies to older therapies were not performed or are currently unavailable.

Research explored whether the combination with a standard care medication was associated with changes in symptom control, with some participants showing a greater change in outcomes compared to monotherapy.

The study population largely excluded individuals with severe kidney impairment. The research documentation described the specific administration context used during the trials. The body of evidence describes the measured outcomes observed in the research trials.

Key Studies & References

1. Efficacy and Safety of Aminocardol in Moderate-to-Severe Chronic Inflammatory Disease: A 52-Week Phase III Randomized, Controlled Trial (The ASCEND Study)
2. Clinical Guideline for the Management of Chronic Inflammatory Arthritis (2023 Update) - National Institute for Health and Care Excellence (NICE)

Common questions about Aminocardol (FAQ)

Q: Is Aminocardol a type of blood thinner?

According to official regulatory documents, Aminocardol (Theophylline) is classified as a bronchodilator, belonging to the Xanthine Derivative pharmacological group. Its primary function is to relax the smooth muscles in the airways. It is not classified as an anticoagulant, which is the term used for blood-thinning medicines.

Q: How quickly does Aminocardol usually start to work?

The rate at which the medicine begins to work is related to the specific dosage form. Immediate-release formulations are designed to reach their highest concentration in the bloodstream within minutes to a few hours. In contrast, extended-release products take longer, typically six to ten hours, to achieve and maintain stable therapeutic levels.

Q: Do people typically feel tired when they first start Aminocardol?

Official safety information indicates that the most common central nervous system (CNS) effects include restlessness, tremors, and insomnia. Since the active substance is a stimulant, effects like fatigue or tiredness are not consistently listed as common side effects. Official guidance suggests contacting a healthcare professional for changes in side effects or energy levels.

Q: Is Aminocardol known to interact with common pain relievers like ibuprofen?

Regulatory labeling specifies several interactions with substances that affect the liver enzyme system (CYP450), which can alter how the body clears the drug. While the product information may not list every Non-Steroidal Anti-Inflammatory Drug (NSAID) by name, regulatory documents emphasize the importance of communicating all medicines, including pain relievers, to the prescribing professional.

Q: Is Aminocardol generally considered a long-term treatment?

Extended-release formulations of Aminocardol are indicated for the ongoing management of chronic conditions, such as the symptoms and airflow obstruction associated with chronic lung diseases and asthma. The indication described in regulatory documents is for sustained, long-term therapeutic use in chronic conditions.

Q: What happens if a dose of Aminocardol is missed?

Regulatory guidance for a missed dose often states to skip the dose and resume the normal schedule at the next scheduled time. The guidance strictly prohibits taking two doses at the same time to compensate for a missed dose.

Q: Is it possible for Aminocardol to change the results of blood tests?

Documented regulatory information shows that high (toxic) concentrations of Theophylline can affect certain blood parameters. These changes may include an increase in blood sugar and calcium, and a decrease in potassium. The active ingredient concentration in the blood is often measured to guide appropriate dosing and to help manage potential risks.

Q: Are there any known interactions between Aminocardol and herbal supplements?

Aminocardol interacts with many substances that can influence liver enzymes involved in drug clearance. While specific herbal supplements may not be individually listed in official documents, regulatory information advises patients to discuss all supplements with a healthcare professional, as they may unintentionally alter the required drug levels.

Q: Does Aminocardol cause weight gain or loss?

Weight gain or weight loss are not consistently documented as common or serious adverse reactions in the official product labeling. However, gastrointestinal side effects like nausea and vomiting are listed, and these may indirectly affect a person's appetite and, subsequently, their weight.

Q: Can Aminocardol affect a person's mood or cause anxiety?

Yes, the stimulant properties of the active drug can lead to central nervous system effects. The official safety profile notes that symptoms such as restlessness, irritability, and nervousness are possible, and these may sometimes be perceived as changes in mood or anxiety.

Q: Are there documented cases of Aminocardol overdose?

Acute and chronic Theophylline toxicity, often referred to as overdose, is a documented safety concern addressed in regulatory information. Severe effects are described and can include persistent vomiting, cardiac arrhythmias (irregular heart rhythm), and potentially seizures.

Q: Is Aminocardol a controlled substance or habit-forming?

Regulatory bodies in major jurisdictions generally do not classify Aminocardol (Theophylline) as a controlled substance. Furthermore, official product information does not indicate that the medicine is known to be habit-forming.

Q: What does 'use conditions' mean in the context of Aminocardol?

In official drug information, 'use conditions' refer to the necessary administrative guidelines and patient circumstances required for safe prescribing. This includes patient eligibility based on age or pre-existing conditions (like heart or liver disease) and the need for therapeutic monitoring, such as blood level checks.

Q: Are there specific instructions for stopping Aminocardol (non-dosing related)?

The regulatory documents do not provide general, non-dosing related instructions for the routine cessation of the drug. However, official guidance indicates that signs of toxicity or a known drug interaction require prompt communication with a healthcare professional.

Q: What if I take another medicine that causes a known interaction with Aminocardol?

Official regulatory guidance indicates that known drug interactions usually necessitate a review of the patient's treatment plan. This may involve possible adjustments to the Aminocardol dosage or other increased monitoring of the drug concentration in the serum.

Storage and Disposal Requirements

The official labeling for Aminocardol (Choline Theophyllinate) defines mandatory storage conditions essential for maintaining product stability and the labeled 3-year shelf life.

Storage Component	Required Condition
Temperature	Store in a cool place.
Protection	Protect from light and moisture; store in a dry place.
Containment	Keep the medicine in its original package.
Safety	Keep all medicines out of reach of children.

Disposal of unused or expired product should follow local guidelines for pharmaceutical waste, as the labeling specifies no special requirements for disposal. Adherence to these rules is required to ensure the product remains stable and safe until its expiration date.